Europe Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033

List of Tables

Introduction to Europe Rare Disease Genetic Testing Market

The Europe rare disease genetic testing market was valued at $1.16 billion in 2023 and is anticipated to reach $4.17 billion by 2033, witnessing a CAGR of 13.60% during the forecast period 2023-2033. The market for genetic testing in rare diseases has experienced notable growth, driven by a rising need for early identification of such conditions. The growing occurrence of rare diseases has been a pivotal factor in this growth trajectory. Moreover, there's a heightened acknowledgment and focus on early detection and prevention, particularly among pediatric populations worldwide, which is anticipated to further drive market growth.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$1.16 Billion
2033 Forecast	$4.17 Billion
CAGR	13.6%

Market Introduction

The Europe rare disease genetic testing market in Europe is witnessing substantial growth driven by several factors. Increasing awareness and advancements in genetic testing technologies have propelled demand for early detection and diagnosis of rare diseases across the continent. Additionally, the rising prevalence of rare diseases in European populations has contributed significantly to market growth. Moreover, there's a growing emphasis on early intervention and personalized medicine, further boosting the adoption of genetic testing for rare diseases. Regulatory initiatives and healthcare policies promoting accessibility to genetic testing services also play a crucial role in market development. As healthcare systems in Europe prioritize precision medicine and improved patient outcomes, the rare disease genetic testing market is poised for continued growth, offering opportunities for innovation and collaboration among stakeholders in the healthcare sector.

Market Segmentation:

Segmentation 1: by Disease Type

Gastroenterology Disease
Endocrine and Metabolism Disease
Cardiovascular Disease
Neurology Disease
Hematology and Oncology Disease
Dermatology Disease
Other Diseases

Segmentation 2: by Technology

Sanger Sequencing
PCR
NGS
Microarrays
Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

Germany
U.K.
France
Italy
Russia
Spain
Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

CENTOGENE N.V.
Eurofins Scientific SE
QIAGEN N.V.

Product Code: BHP1926SS

Executive Summary

Scope of the Study

Research Methodology

1 Market

1.1 Global Market Outlook
- 1.1.1 Product Definition
- 1.1.2 Inclusion and Exclusion Criteria
  - 1.1.2.1 Inclusion Criteria
  - 1.1.2.2 Exclusion Criteria
- 1.1.3 Market Overview
  - 1.1.3.1 Market Footprint
  - 1.1.3.2 Market Size and Future Growth Potential
- 1.1.4 COVID-19 Impact on the Market
  - 1.1.4.1 Impact on Research and Clinical Operations
  - 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
1.2 Industry Analysis
- 1.2.1 Regulatory Framework
  - 1.2.1.1 Legal Requirements and Framework in the U.S.
  - 1.2.1.2 Legal Requirements and Framework in Europe
    - 1.2.1.2.1 U.K.
    - 1.2.1.2.2 Spain
  - 1.2.1.3 Legal Requirements and Framework in Asia-Pacific
    - 1.2.1.3.1 Japan
    - 1.2.1.3.2 China
    - 1.2.1.3.3 India
    - 1.2.1.3.4 Taiwan
- 1.2.2 Patent Analysis
  - 1.2.2.1 Patent Filing Trend (by Country)
  - 1.2.2.2 Patent Filing Trend (by Year)
- 1.2.3 Funding Scenario
1.3 Market Dynamics
- 1.3.1 Overview
- 1.3.2 Market Drivers
  - 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
  - 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
  - 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
- 1.3.3 Market Challenges
  - 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
  - 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
- 1.3.4 Market Opportunities
  - 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
  - 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
  - 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Europe

2.1 Europe Rare Disease Genetic Testing Market
- 2.1.1 Market Dynamics
  - 2.1.1.1 Impact Analysis
- 2.1.2 Market Sizing and Forecast
  - 2.1.2.1 Europe Rare Disease Genetic Testing Market (by Disease Type)
  - 2.1.2.2 Europe Rare Disease Genetic Testing Market (by Technology)
  - 2.1.2.3 Europe Rare Disease Genetic Testing Market (by Country)
    - 2.1.2.3.1 Germany
      - 2.1.2.3.1.1 Market Dynamics
      - 2.1.2.3.1.2 Market Size and Forecast
      - 2.1.2.3.1.2.1 Germany Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.1.2.2 Germany Rare Disease Genetic Testing Market (by Technology)
    - 2.1.2.3.2 U.K.
      - 2.1.2.3.2.1 Market Dynamics
      - 2.1.2.3.2.2 Market Size and Forecast
      - 2.1.2.3.2.2.1 U.K Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.2.2.2 U.K. Rare Disease Genetic Testing Market (by Technology)
    - 2.1.2.3.3 France
      - 2.1.2.3.3.1 Market Dynamics
      - 2.1.2.3.3.2 Market Size and Forecast
      - 2.1.2.3.3.2.1 France Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.3.2.2 France Rare Disease Genetic Testing Market (by Technology)
    - 2.1.2.3.4 Italy
      - 2.1.2.3.4.1 Market Dynamics
      - 2.1.2.3.4.2 Market Size and Forecast
      - 2.1.2.3.4.2.1 Italy Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.4.2.2 Italy Rare Disease Genetic Testing Market (by Technology)
    - 2.1.2.3.5 Spain
      - 2.1.2.3.5.1 Market Dynamics
      - 2.1.2.3.5.2 Market Size and Forecast
      - 2.1.2.3.5.2.1 Spain Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.5.2.2 Spain Rare Disease Genetic Testing Market (by Technology)
    - 2.1.2.3.6 Russia
      - 2.1.2.3.6.1 Market Dynamics
      - 2.1.2.3.6.2 Market Size and Forecast
      - 2.1.2.3.6.2.1 Russia Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.6.2.2 Russia Rare Disease Genetic Testing Market (by Technology)
    - 2.1.2.3.7 Rest-of-Europe
      - 2.1.2.3.7.1 Market Dynamics
      - 2.1.2.3.7.2 Market Size and Forecast
      - 2.1.2.3.7.2.1 Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type)
      - 2.1.2.3.7.2.2 Rest-of-Europe Rare Disease Genetic Testing Market (by Technology)

3 Company Profiles

3.1 Overview
- 3.1.1 CENTOGENE N.V.
  - 3.1.1.1 Company Overview
  - 3.1.1.2 Role of CENTOGENE N.V. in the Rare Disease Genetic Testing Market
  - 3.1.1.3 Financials
  - 3.1.1.4 Recent Developments
  - 3.1.1.5 Analyst Perspective
- 3.1.2 Eurofins Scientific SE
  - 3.1.2.1 Company Overview
  - 3.1.2.2 Role of Eurofins Scientific SE in the Rare Disease Genetic Testing Market
  - 3.1.2.3 Financials
  - 3.1.2.4 Recent Developments
  - 3.1.2.5 Analyst Perspective
- 3.1.3 QIAGEN N.V.
  - 3.1.3.1 Company Overview
  - 3.1.3.2 Role of QIAGEN N.V. in the Rare Disease Genetic Testing Market
  - 3.1.3.3 Financials
  - 3.1.3.4 Recent Developments
  - 3.1.3.5 Analyst Perspective

Product Code: BHP1926SS

List of Figures

Figure 1: Global Prevalence Rare Disease, 2022
Figure 2: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
Figure 3: Europe Rare Disease Genetic Testing Market, Market Dynamics
Figure 4: Most Frequently Studied Rare Diseases, 2021
Figure 5: Europe Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
Figure 6: Europe Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
Figure 7: Rare Disease Genetic Testing Market (by Region), $Billion, 2022 and 2033
Figure 8: Share of Key Developments and Strategies, January 2019-June 2023
Figure 9: Rare Disease Genetic Testing Market: Research Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Europe Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
Figure 14: Regulatory Scenario in Europe (by Country)
Figure 15: Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
Figure 16: Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
Figure 17: NIH Funding on Rare Diseases, $Million, 2013-2023
Figure 18: Rare Disease Genetic Testing Market Dynamics
Figure 19: Rare Disease Prevalence in India, 2022
Figure 20: Global Prevalence of Rare Diseases, 2022
Figure 21: Most Frequently Studied Rare Diseases, 2021
Figure 22: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
Figure 23: Rare Disease Genetic Testing Market Share (by Region), 2022-2033
Figure 24: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
Figure 25: Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 26: Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 27: Europe Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
Figure 28: Germany Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 29: Germany Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 30: Germany Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 31: U.K. Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 32: U.K. Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 33: U.K. Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 34: France Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 35: France Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 36: France Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 37: Italy Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 38: Italy Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 39: Italy Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 40: Spain Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 41: Spain Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 42: Spain Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 43: Russia Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 44: Russia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 45: Russia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 46: Rest-of-Europe Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 47: Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 48: Rest-of-Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 49: Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
Figure 50: CENTOGENE N.V.: Product Portfolio
Figure 51: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
Figure 52: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2020-2022
Figure 53: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2020-2022
Figure 54: CENTOGENE N.V.: R&D Expenditure, $Million, 2020-202
Figure 55: Eurofins Scientific SE: Product Portfolio
Figure 56: Eurofins Scientific SE: Overall Financials, $Million, 2020-2022
Figure 57: Eurofins Scientific SE: Net Revenue (by Segment), $Million, 2020-2022
Figure 58: Eurofins Scientific SE: Net Revenue (by Region), $Million, 2020-2022
Figure 59: QIAGEN N.V.: Product Portfolio
Figure 60: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 61: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 62: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 63: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022

List of Tables

Table 1: Key Questions Answered in the Report
Table 2: Funding for Rare Disease Research
Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
Table 5: Europe Rare Disease Genetic Testing Market, Impact Analysis

Europe Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033

Description

Table of Contents

List of Tables

Table of Contents

Executive Summary

Scope of the Study

1 Market

2 Europe

3 Company Profiles

List of Figures

List of Tables